Performance | Kangsheng Pharmaceuticals Earned 18% More Last Year

SighingCashier

2026-03-26 04:44:37

Abstract generation in progress

Kangchen Pharmaceutical (01681) announced its full-year results for the year ending 2025, with shareholders’ profit attributable to 1.078 billion yuan (RMB), an 18.41% increase year-on-year. Basic earnings per share are 1.27 yuan, with a final dividend of HKD 0.4.

During the period, revenue reached 3.417 billion yuan, up 15.17% year-on-year.

Looking ahead to 2026, the group expects that the normalization of medical insurance cost control and further refinement of centralized procurement will continue. Whether products will be severely impacted by centralized procurement depends on their “irreplaceable value.” Additionally, the implementation of diversified payment systems, accelerated development of innovative drug tracks, digital transformation, and full-process optimization of traditional Chinese medicine quality will bring new opportunities. The group will be guided by an overall strategy, focusing on the nine-character policy of “driving growth, improving efficiency, and strengthening execution,” to promote high-quality development.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.